Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Cumberland Pharmaceuticals (CPIX) over the last 13 years, with Dec 2024 value amounting to -$1.5 million.

  • Cumberland Pharmaceuticals' Gains from Investment Securities rose 101.95% to $9,651 in Q3 2025 from the same period last year, while for Sep 2025 it was -$431,503, marking a year-over-year increase of 63.19%. This contributed to the annual value of -$1.5 million for FY2024, which is 16.51% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Gains from Investment Securities of -$1.5 million as of FY2024, which was down 16.51% from -$1.3 million recorded in FY2023.
  • Cumberland Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $4.6 million during FY2022, with a 5-year trough of -$1.5 million in FY2024.
  • Over the past 3 years, Cumberland Pharmaceuticals' median Gains from Investment Securities value was -$1.3 million (recorded in 2023), while the average stood at $625,445.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Gains from Investment Securities spiked by 1,404,068.81% in 2022, and later slumped by 127.31% in 2023.
  • Yearly analysis of 5 years shows Cumberland Pharmaceuticals' Gains from Investment Securities stood at -$91,486 in 2020, then spiked by 99.64% to -$327 in 2021, then soared by 1,404,068.81% to $4.6 million in 2022, then crashed by 127.31% to -$1.3 million in 2023, then dropped by 16.51% to -$1.5 million in 2024.